A detailed history of Moors & Cabot, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Moors & Cabot, Inc. holds 21,421 shares of LLY stock, worth $16.7 Million. This represents 0.97% of its overall portfolio holdings.

Number of Shares
21,421
Previous 20,882 2.58%
Holding current value
$16.7 Million
Previous $18.9 Million 0.38%
% of portfolio
0.97%
Previous 1.02%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$772.14 - $960.02 $416,183 - $517,450
539 Added 2.58%
21,421 $19 Million
Q2 2024

Aug 09, 2024

BUY
$724.87 - $909.04 $890,865 - $1.12 Million
1,229 Added 6.25%
20,882 $18.9 Million
Q1 2024

May 08, 2024

SELL
$592.2 - $792.28 $394,405 - $527,658
-666 Reduced 3.28%
19,653 $15.3 Million
Q4 2023

Feb 14, 2024

SELL
$525.19 - $619.13 $44,641 - $52,626
-85 Reduced 0.42%
20,319 $11.8 Million
Q3 2023

Nov 07, 2023

SELL
$434.7 - $599.3 $639,443 - $881,570
-1,471 Reduced 6.72%
20,404 $11 Million
Q2 2023

Aug 09, 2023

SELL
$350.74 - $468.98 $84,177 - $112,555
-240 Reduced 1.09%
21,875 $10.3 Million
Q1 2023

May 04, 2023

BUY
$310.63 - $364.82 $1.41 Million - $1.66 Million
4,541 Added 25.84%
22,115 $7.59 Million
Q4 2022

Feb 09, 2023

SELL
$321.55 - $374.67 $396,471 - $461,968
-1,233 Reduced 6.56%
17,574 $6.43 Million
Q4 2022

Feb 06, 2023

SELL
$321.55 - $374.67 $857,895 - $999,619
-2,668 Reduced 12.42%
18,807 $6.88 Million
Q3 2022

Nov 07, 2022

SELL
$296.48 - $337.87 $482,076 - $549,376
-1,626 Reduced 7.04%
21,475 $6.94 Million
Q2 2022

Aug 08, 2022

BUY
$278.73 - $327.27 $47,105 - $55,308
169 Added 0.74%
23,101 $7.49 Million
Q1 2022

May 13, 2022

SELL
$234.69 - $291.66 $216,618 - $269,202
-923 Reduced 3.87%
22,932 $6.57 Million
Q4 2021

Feb 14, 2022

BUY
$224.85 - $279.04 $743,354 - $922,506
3,306 Added 16.09%
23,855 $6.59 Million
Q3 2021

Dec 08, 2021

BUY
$221.6 - $272.71 $4.55 Million - $5.6 Million
20,549 New
20,549 $4.75 Million
Q3 2021

Nov 05, 2021

SELL
$221.6 - $272.71 $4.04 Million - $4.97 Million
-18,213 Closed
0 $0
Q2 2021

Aug 10, 2021

SELL
$180.55 - $233.54 $31,235 - $40,402
-173 Reduced 0.94%
18,213 $4.18 Million
Q1 2021

May 12, 2021

BUY
$164.32 - $212.72 $74,765 - $96,787
455 Added 2.54%
18,386 $3.43 Million
Q4 2020

Feb 11, 2021

BUY
$130.46 - $172.63 $344,414 - $455,743
2,640 Added 17.27%
17,931 $3.03 Million
Q3 2020

Nov 09, 2020

SELL
$146.22 - $169.13 $168,591 - $195,006
-1,153 Reduced 7.01%
15,291 $2.26 Million
Q2 2020

Aug 13, 2020

SELL
$136.42 - $164.18 $271,339 - $326,554
-1,989 Reduced 10.79%
16,444 $2.7 Million
Q1 2020

May 12, 2020

SELL
$119.05 - $147.35 $2,261 - $2,799
-19 Reduced 0.1%
18,433 $2.56 Million
Q4 2019

Jan 28, 2020

SELL
$106.92 - $132.43 $84,146 - $104,222
-787 Reduced 4.09%
18,452 $2.42 Million
Q3 2019

Oct 22, 2019

BUY
$106.79 - $116.16 $112,556 - $122,432
1,054 Added 5.8%
19,239 $2.15 Million
Q2 2019

Jul 18, 2019

BUY
$110.79 - $129.32 $202,524 - $236,396
1,828 Added 11.18%
18,185 $2.01 Million
Q1 2019

May 06, 2019

SELL
$111.31 - $131.02 $1.82 Million - $2.14 Million
-16,357 Reduced 50.0%
16,357 $2.13 Million
Q1 2019

May 01, 2019

BUY
$111.31 - $131.02 $1.8 Million - $2.12 Million
16,208 Added 98.19%
32,714 $4.25 Million
Q4 2018

Feb 13, 2019

SELL
$105.9 - $118.64 $1.43 Million - $1.6 Million
-13,460 Reduced 44.92%
16,506 $1.91 Million
Q3 2018

Nov 14, 2018

SELL
$85.86 - $107.31 $65,511 - $81,877
-763 Reduced 2.48%
29,966 $3.21 Million
Q2 2018

Aug 14, 2018

BUY
$75.7 - $86.88 $12,339 - $14,161
163 Added 0.53%
30,729 $2.63 Million
Q1 2018

May 18, 2018

BUY
$74.21 - $87.6 $42,522 - $50,194
573 Added 1.91%
30,566 $2.37 Million
Q4 2017

Feb 13, 2018

SELL
$81.94 - $87.89 $55,145 - $59,149
-673 Reduced 2.19%
29,993 $2.53 Million
Q3 2017

Nov 16, 2017

BUY
$77.07 - $85.54 $32,369 - $35,926
420 Added 1.39%
30,666 $2.62 Million
Q2 2017

Aug 15, 2017

BUY
N/A
30,246
30,246 $2.49 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $740B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Moors & Cabot, Inc. Portfolio

Follow Moors & Cabot, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Moors & Cabot, Inc. with notifications on news.